A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Shelley Potter; Kerry Avery; Rosina Ahmed; Jana De Boniface; Sanjoy Chatterjee; David Dodwell; Peter Dubsky; Jingjing Federmann; Sandra Finestone; Michael Gnant; Dominik Hlauschek; Hiroji Iwata; Michael Y. Jiang; Orit Kaidar-Person; Han-Byoel Lee; Mairead Mackenzie; Anne Meyn; Philip Poortmans; Fiorita Poulakaki; Andrea L. Richardson; Karla A. Sepulveda; Andrew J. Spillane; Alastair M. Thompson; Gustavo Werutsky; Philipp Wittmann; Jean L. Wright; Nicholas Zdenkowski; Katherine Cowan; Stuart A. McIntosh; PRECEDENT Study Group

doi:10.1038/s41523-025-00824-w

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Shelley Potter^*, Kerry Avery, Rosina Ahmed, Jana De Boniface, Sanjoy Chatterjee, David Dodwell, Peter Dubsky, Jingjing Federmann, Sandra Finestone, Michael Gnant, Dominik Hlauschek, Hiroji Iwata, Michael Y. Jiang, Orit Kaidar-Person, Han-Byoel Lee, Mairead Mackenzie, Anne Meyn, Philip Poortmans, Fiorita Poulakaki, Andrea L. RichardsonKarla A. Sepulveda, Andrew J. Spillane, Alastair M. Thompson, Gustavo Werutsky, Philipp Wittmann, Jean L. Wright, Nicholas Zdenkowski, Katherine Cowan, Stuart A. McIntosh, PRECEDENT Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.

Original language	English
Article number	116
Number of pages	10
Journal	npj Breast Cancer
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41523-025-00824-w
Publication status	Published - 28 Oct 2025

Keywords

DEFINITIONS

Access to Document

10.1038/s41523-025-00824-wLicence: CC BY

Cite this

Potter, S., Avery, K., Ahmed, R., De Boniface, J., Chatterjee, S., Dodwell, D., Dubsky, P., Federmann, J., Finestone, S., Gnant, M., Hlauschek, D., Iwata, H., Jiang, M. Y., Kaidar-Person, O., Lee, H.-B., Mackenzie, M., Meyn, A., Poortmans, P., Poulakaki, F., ... PRECEDENT Study Group (2025). A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials. npj Breast Cancer, 11(1), Article 116. https://doi.org/10.1038/s41523-025-00824-w

@article{9aaf33c54177442bb99b2148e182edb9,

title = "A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials",

abstract = "Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.",

keywords = "DEFINITIONS",

author = "Shelley Potter and Kerry Avery and Rosina Ahmed and \{De Boniface\}, Jana and Sanjoy Chatterjee and David Dodwell and Peter Dubsky and Jingjing Federmann and Sandra Finestone and Michael Gnant and Dominik Hlauschek and Hiroji Iwata and Jiang, \{Michael Y.\} and Orit Kaidar-Person and Han-Byoel Lee and Mairead Mackenzie and Anne Meyn and Philip Poortmans and Fiorita Poulakaki and Richardson, \{Andrea L.\} and Sepulveda, \{Karla A.\} and Spillane, \{Andrew J.\} and Thompson, \{Alastair M.\} and Gustavo Werutsky and Philipp Wittmann and Wright, \{Jean L.\} and Nicholas Zdenkowski and Katherine Cowan and McIntosh, \{Stuart A.\} and \{PRECEDENT Study Group\}",

year = "2025",

month = oct,

day = "28",

doi = "10.1038/s41523-025-00824-w",

language = "English",

volume = "11",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Publishing Group",

number = "1",

}

Potter, S, Avery, K, Ahmed, R, De Boniface, J, Chatterjee, S, Dodwell, D, Dubsky, P, Federmann, J, Finestone, S, Gnant, M, Hlauschek, D, Iwata, H, Jiang, MY, Kaidar-Person, O, Lee, H-B, Mackenzie, M, Meyn, A, Poortmans, P, Poulakaki, F, Richardson, AL, Sepulveda, KA, Spillane, AJ, Thompson, AM, Werutsky, G, Wittmann, P, Wright, JL, Zdenkowski, N, Cowan, K, McIntosh, SA & PRECEDENT Study Group 2025, 'A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials', npj Breast Cancer, vol. 11, no. 1, 116. https://doi.org/10.1038/s41523-025-00824-w

TY - JOUR

T1 - A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

AU - Potter, Shelley

AU - Avery, Kerry

AU - Ahmed, Rosina

AU - De Boniface, Jana

AU - Chatterjee, Sanjoy

AU - Dodwell, David

AU - Dubsky, Peter

AU - Federmann, Jingjing

AU - Finestone, Sandra

AU - Gnant, Michael

AU - Hlauschek, Dominik

AU - Iwata, Hiroji

AU - Jiang, Michael Y.

AU - Kaidar-Person, Orit

AU - Lee, Han-Byoel

AU - Mackenzie, Mairead

AU - Meyn, Anne

AU - Poortmans, Philip

AU - Poulakaki, Fiorita

AU - Richardson, Andrea L.

AU - Sepulveda, Karla A.

AU - Spillane, Andrew J.

AU - Thompson, Alastair M.

AU - Werutsky, Gustavo

AU - Wittmann, Philipp

AU - Wright, Jean L.

AU - Zdenkowski, Nicholas

AU - Cowan, Katherine

AU - McIntosh, Stuart A.

AU - PRECEDENT Study Group

PY - 2025/10/28

Y1 - 2025/10/28

N2 - Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.

AB - Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.

KW - DEFINITIONS

U2 - 10.1038/s41523-025-00824-w

DO - 10.1038/s41523-025-00824-w

M3 - Article

SN - 2374-4677

VL - 11

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 116

ER -

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Abstract

Keywords

Access to Document

Fingerprint

Cite this